Does Aetna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review

Short version: Aetna is part of CVS Health, and its pharmacy benefit is administered by its sister company CVS Caremark. That single fact drives almost everything about Aetna weight-loss-drug coverage. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza) are widely covered with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are covered only when your employer elected the anti-obesity-medication benefit — AOM coverage is an employer rider, not a standard inclusion. And the single biggest 2025 event: on July 1, 2025 CVS Caremark dropped Zepbound from its standard commercial formularies and made Wegovy the preferred anti-obesity GLP-1, which flowed straight through to Aetna commercial plans. As of October 1, 2026 Caremark is restoring Zepbound as a co-preferred option — but only on plans that adopt the standard template.

At a glance

• Aetna GLP-1 coverage for type 2 diabetes: generally YES with prior authorization. Ozempic, Mounjaro, Trulicity, Rybelsus, and Victoza appear on most Aetna commercial formularies for the T2D indication, adjudicated by CVS Caremark.^[1]
• Aetna GLP-1 coverage for chronic weight management: only if your employer elected the AOM benefit. Wegovy, Zepbound, and Saxenda are covered when the plan includes anti-obesity medications and excluded when the employer carved them out. This is the single biggest determinant of coverage.^[1]
• The 2025 Caremark switch: effective July 1, 2025, CVS Caremark removed Zepbound from its Standard, Advanced Control, and Value commercial formularies and made Wegovy the preferred weight-loss GLP-1 after a rebate deal with Novo Nordisk. Aetna commercial plans following the standard Caremark template inherited that change.^[7][8]
• The 2026 reversal: after patient backlash and a lawsuit, CVS Caremark announced Zepbound returns as an additional preferred (co-preferred) option on standard commercial formularies effective October 1, 2026, and removed the new-to-market block on the oral GLP-1 Foundayo (orforglipron) effective June 1, 2026 — both subject to each plan adopting the change.^[9]
• Aetna Medicare (Part D): NO for weight-loss-only Wegovy/Zepbound/Saxenda — federal law excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.”^[2] YES for the Zepbound obstructive-sleep-apnea indication post-12/20/2024 and (formulary-dependent) Wegovy for cardiovascular risk reduction.^[5][6]
• Aetna Medicaid (managed care): defers to the state. Aetna Better Health managed-care plans follow each state Medicaid program's preferred drug list and weight-loss-drug rules, which vary widely by state.^[1]
• Typical PA pattern (Wegovy): BMI ≥ 30, OR BMI ≥ 27 with a weight-related comorbidity, age 18+, AND documented participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, increased activity) for at least 6 months. Initial approval ~7 months; continuation ~12 months conditioned on ≥5% baseline weight loss.^[3]

Why Aetna coverage is really CVS Caremark coverage

Aetna does not run its own pharmacy benefit. Since CVS Health acquired Aetna in 2018, Aetna's prescription drug benefit has been administered by CVS Caremark, the CVS Health pharmacy-benefit manager (PBM). The practical chain is: Aetna sells the medical plan to your employer, CVS Caremark publishes the formulary and adjudicates prior authorization, and you fill prescriptions at retail pharmacies that submit claims back to Caremark.^[1] For a Caremark-specific breakdown — its preferred formularies, the 2025 Zepbound-to-Wegovy switch, and the 2026 reversal — see does CVS Caremark cover weight-loss drugs.

That means three things for weight-loss-drug coverage:

1. The formulary is a Caremark formulary. Whether Wegovy or Zepbound is preferred, non-preferred, or excluded for weight loss is set by CVS Caremark's rebate-driven formulary strategy — not by Aetna's medical side. When Caremark changed its preferred weight-loss GLP-1 in 2025, Aetna plans on the standard template changed with it.^[7]
2. Prior authorization is adjudicated by Caremark. PA requests route through the CVS Caremark prescriber portal (or fax), not an Aetna-specific portal. The clinical criteria live in Aetna's Pharmacy Clinical Policy Bulletins, which Caremark applies.^[3]
3. Your employer still controls the benefit class. Caremark's standard formulary is a template. Self-funded employers (a large share of Aetna's commercial book) choose whether to include anti-obesity medications at all, and whether to follow the standard formulary or a custom one. Two people with “Aetna” cards can have completely different weight-loss-drug coverage.^[1]

GLP-1 coverage for type 2 diabetes (widely covered)

For the type 2 diabetes indication, GLP-1 receptor agonists are generally on-formulary on Aetna commercial plans with prior authorization. The agents commonly covered:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD. See our semaglutide drug page.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D. See our tirzepatide drug page.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.

Typical Aetna/Caremark PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Because T2D is not a weight-loss indication, these drugs sit on the diabetes side of the formulary and are not affected by the AOM-rider question.^[1]

GLP-1 coverage for chronic weight management (employer rider)

This is where Aetna coverage becomes conditional. The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg, indication: chronic weight management in adults + pediatric patients aged 12+ with obesity, plus cardiovascular risk reduction, per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b^[5]), Zepbound (tirzepatide, indication: chronic weight management + moderate-to-severe OSA in adults with obesity, per DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[6]), and Saxenda (liraglutide 3.0 mg) — are covered by Aetna only when the employer plan includes the anti-obesity-medication benefit.

AOM coverage is not a standard inclusion. It is effectively a rider that the plan sponsor (your employer, or for individual plans the plan design itself) elects to buy. Many employers carve anti-obesity medications out of the prescription benefit entirely to control premium cost — and when they do, no amount of medical-necessity documentation will produce coverage, because the benefit class itself is excluded.^[1]

When the plan does include AOMs, Aetna's published Wegovy PA criteria are well-defined:^[3]

• BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — for the Zepbound OSA pathway — moderate-to-severe obstructive sleep apnea).
• Age 18 or older for the weight-management indication (12+ for the pediatric obesity indication; 45+ for the Wegovy cardiovascular-risk indication).
• Documented participation in a comprehensive weight-management program — behavioral modification, reduced-calorie diet, and increased physical activity with follow-up — for at least 6 months prior to the request.
• Initial approval is typically 7 months; continuation is typically 12 months, conditioned on maintaining at least 5% baseline weight loss (or ongoing weight reduction). Quantity limits apply (1-3 cartons/month by dose strength).

For the underlying weight-loss magnitudes that anchor these PA decisions, see our best semaglutide providers and best tirzepatide providers rankings.

The 2025 Caremark Zepbound-to-Wegovy switch (and the 2026 reversal)

The most consequential change to Aetna weight-loss coverage in years did not originate on Aetna's medical side at all — it came from the PBM. Effective July 1, 2025, CVS Caremark removed Zepbound (tirzepatide) from its Standard, Advanced Control, and Value commercial formularies — the templates most employers use — and designated Wegovy (semaglutide 2.4 mg) as the single preferred anti-obesity GLP-1, following a rebate agreement with Novo Nordisk.^[7][8]

For Aetna commercial members on plans following the standard Caremark template, the practical effect was: if your employer included AOM coverage, Wegovy was the covered weight-loss GLP-1 and Zepbound was no longer covered for weight loss as of July 1, 2025. Members already on Zepbound generally had to switch to Wegovy or pursue a formulary exception (for example, documented intolerance or insufficient response to Wegovy). For dose-conversion context when switching tirzepatide-to-semaglutide, talk to your prescriber before changing agents.

After significant patient backlash and litigation, CVS Caremark announced a partial reversal: Zepbound returns as an additional preferred (co-preferred) option on the standard commercial formulary template effective October 1, 2026, putting Wegovy and Zepbound side-by-side as co-preferred weight-loss GLP-1s. Separately, Caremark removed the new-to-market block on Foundayo (orforglipron, an oral GLP-1) effective June 1, 2026 where plans approve coverage.^[9]

Aetna Medicare (Part D) — federal exclusion

Aetna is one of the largest Medicare Part D and Medicare Advantage carriers in the country. Like every Medicare Part D plan, Aetna Medicare operates under Social Security Act §1860D-2(e)(2)(A), which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[2] This is a federal statutory exclusion — Aetna Medicare cannot cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications regardless of medical-necessity documentation.

Three exceptions where Aetna Medicare CAN cover otherwise-excluded GLP-1s:

• Ozempic / Mounjaro / Trulicity for T2D. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.
• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024. The Zepbound label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[6]) lists OSA in adults with obesity as a separately FDA-approved indication — and because it is not weight loss, the Part D exclusion does not block coverage. Aetna Medicare can cover Zepbound for OSA subject to PA. The SURMOUNT-OSA trial is the underlying evidence base.^[10]
• Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication is reducing the risk of major adverse cardiovascular events in adults with established CVD and overweight/obesity.^[5] As a non-weight-loss indication, this is coverable on Medicare Part D — though individual Aetna Medicare formularies vary on how aggressively they cover it. Confirm with your specific plan's formulary.

Aetna Medicaid managed care — defers to the state

Aetna participates in Medicaid managed care through Aetna Better Health plans in numerous states. For Medicaid managed-care members, weight-loss-drug coverage is governed by the state Medicaid program, not by Aetna's commercial formulary. Each state decides whether its Medicaid program covers anti-obesity GLP-1s, and the rules vary widely — some states cover Wegovy/Zepbound for weight loss with PA, others exclude weight-loss GLP-1s entirely while continuing to cover the T2D indication.^[1]

Aetna Better Health plans follow the applicable state Medicaid preferred drug list and PA criteria. If you have an Aetna Better Health Medicaid plan, the authoritative source is your state Medicaid program's drug coverage rules combined with your Aetna Better Health formulary — not Aetna's commercial documents.

How to find out if YOUR Aetna plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. CVS Caremark member portal → drug-cost / formulary lookup. Because Aetna's pharmacy benefit is administered by CVS Caremark, the canonical formulary tool is the Caremark portal (or the Aetna member site, which links to it). Sign in, search “Wegovy” or “Zepbound,” and the result shows the tier, PA requirement, and whether the AOM benefit applies to your plan.^[1]
2. Phone the number on your Aetna/Caremark card. Ask specifically: “Does my plan include anti-obesity-medication coverage? Is (drug name) covered for chronic weight management, what tier, and what is the PA requirement?” The AOM-rider question is the one that matters most.
3. Ask your HR or benefits administrator about the AOM rider. For employer-sponsored plans, HR knows whether the plan bought anti-obesity-medication coverage and whether it follows the standard Caremark formulary or a custom one. This is often faster than the portal for the rider question.
4. Request the Summary of Benefits and Coverage (SBC) and the prescription-drug rider. The SBC and drug rider state whether AOMs are an excluded benefit class. If they are excluded, that is dispositive.

Prior authorization process at Aetna (via CVS Caremark)

Because the benefit is PBM-administered, the PA flow runs through CVS Caremark:

1. Your prescriber evaluates you against Aetna's published Pharmacy Clinical Policy Bulletin criteria (BMI ≥ 30, or ≥ 27 with comorbidity, age 18+, plus the documented 6-month comprehensive weight-management program for Wegovy/Zepbound).^[3]
2. If criteria are met, the prescriber submits the PA through the CVS Caremark prescriber portal (electronic PA) or by fax to Caremark — not an Aetna-specific portal.
3. CVS Caremark adjudicates the PA against Aetna's clinical criteria. Standard turnaround is typically within a few business days for non-urgent requests; expedited review is available for urgent cases.
4. If approved, you fill at a participating retail or mail-order pharmacy and the plan copay/tier applies. Initial approval is typically 7 months; continuation requires documented ≥5% baseline weight loss.^[3]

If denied: Aetna appeal pathway

Aetna commercial members have a defined appeal pathway plus an external review track:

1. First-level internal appeal. You or your prescriber submit a written appeal within the timeframe on the denial notice (commonly 180 days for commercial plans), adding clinical documentation — for example, the 6-month weight-management program records, comorbidity documentation, or evidence of intolerance/insufficient response to the preferred agent (relevant for a Wegovy-vs-Zepbound exception request).
2. Second-level internal appeal if the first is upheld, typically reviewed by a different clinician.
3. External review (IRO). If internal appeals are exhausted, fully-insured commercial members can request an independent external review by an Independent Review Organization, generally binding on the plan; the pathway routes through the relevant state insurance regulator's external-review program.
4. ERISA self-funded plans. For the large share of Aetna members on self-funded employer plans, appeals follow ERISA's federal framework, and the employer plan sponsor's terms govern — including whether the AOM benefit exists at all. If AOMs are a carved-out benefit class, that is a plan-design exclusion, not a medical-necessity denial, and is generally not appealable on clinical grounds.

If Aetna denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Request a formulary exception (the Wegovy/Zepbound switch case). If your plan covers one preferred weight-loss GLP-1 and you cannot tolerate it or it did not work, your prescriber can request a formulary exception for the non-preferred agent with documentation. This is the most common path for members caught in the 2025 Caremark switch.
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically $149-$349/month. Not brand Wegovy or Zepbound — the active ingredient is the same, but quality and supply-chain rigor vary. Diligence matters.
• LillyDirect Self Pay Pharmacy single-dose vials. Roughly $299/month (2.5 mg) up to ~$699/month (10/12.5/15 mg) as of the December 2025 price reduction. Cash-pay; no insurance involvement.
• The Zepbound OSA pathway. If you have a moderate-to-severe OSA diagnosis (AHI ≥ 15), your prescriber can submit a Zepbound PA for the OSA indication, not weight loss — including on Aetna Medicare, where the Part D weight-loss exclusion does not apply.^[6]
• Wegovy for cardiovascular risk reduction. If you have established CVD plus overweight/obesity, your prescriber can submit a Wegovy PA for the CV-risk-reduction indication — a non-weight-loss indication coverable even on Medicare.^[5]
• Compare other payers. For how an integrated HMO handles the same drugs differently, see our Kaiser Permanente weight-loss-drug coverage review, and our broader insurance coverage hub.

For mechanism-of-action context and the underlying weight-loss magnitudes (STEP-1 semaglutide -14.9% body weight at 68 weeks^[7] — see references; SURMOUNT-1 tirzepatide 15 mg -20.9% at 72 weeks^[8]; SURMOUNT-2 in T2D + obesity^[9]), and provider options, see our best semaglutide providers and best tirzepatide providers rankings, plus the semaglutide and tirzepatide drug pages.

Verdict — what most Aetna members should expect

For the median Aetna member asking does Aetna cover weight loss drugs: the answer splits cleanly by indication and by whether your employer bought the AOM benefit:

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza): generally YES with CVS Caremark prior authorization confirming the T2D diagnosis.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): only if your employer elected the anti-obesity-medication rider. From July 1, 2025 the Caremark standard formulary preferred Wegovy and dropped Zepbound; from October 1, 2026 Zepbound returns as co-preferred — but only on plans that adopt the standard template. Verify on the CVS Caremark portal.
3. Aetna Medicare members: NO for weight-loss-only; YES for Zepbound OSA (post-12/20/2024) and (formulary-dependent) Wegovy CV-risk-reduction.
4. Aetna Better Health Medicaid members: defers to your state Medicaid program's rules — varies widely by state.

The PBM-administered model means the formulary is a moving target driven by rebate negotiations — the 2025 Zepbound drop and 2026 co-preferred reversal are the clearest example in recent memory. The single most important question for any Aetna member is not “is the drug on the formulary” but “did my employer include the anti-obesity-medication benefit at all.”

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• GLP-1 insurance coverage hub